{"brief_title": "Phase II Study of High-Dose Cyclophosphamide in Patients With Severe Autoimmune Hematologic Disease", "brief_summary": "OBJECTIVES: I. Determine the response rate and 1-year event-free survival in patients with severe autoimmune hematologic disease treated with high-dose cyclophosphamide.", "detailed_description": "PROTOCOL OUTLINE: Patients receive high-dose cyclophosphamide IV on days 1-4 and filgrastim (G-CSF) starting on day 10 and continuing until blood counts recover. Patients are followed at 1, 3, 6, and 12 months and then annually thereafter.", "condition": "Autoimmune Diseases", "intervention_type": "Drug", "intervention_name": "filgrastim", "criteria": "PROTOCOL ENTRY CRITERIA: --Disease Characteristics-- - Diagnosis of severe autoimmune hematologic disease Autoimmune hemolytic anemia OR Immune thrombocytopenia - Failure of at least 2 standard treatment approaches (e.g., prednisone therapy, splenectomy, intravenous immunoglobulin, or other immunosuppressants) - Inability to taper prednisone dose to less than 10 mg/day OR Autoimmune neutropenia including the following: Felty's syndrome OR Disorders of large granular lymphocytes with recurrent infections or absolute neutrophil count less than 200/mm3 --Prior/Concurrent Therapy-- - See Disease Characteristics --Patient Characteristics-- - Age: Not specified - Performance status: Not specified - Hematopoietic: See Disease Characteristics - Hepatic: Not specified - Renal: Creatinine no greater than 2.5 mg/dL - Cardiovascular: Ejection fraction at least 40% - Pulmonary: FVC, FEV1, or DLCO at least 50% predicted Other: - Not pregnant or nursing - Negative pregnancy test - Fertile patients must use effective contraception - Not preterminal or moribund", "gender": "All", "minimum_age": "N/A", "maximum_age": "N/A", "healthy_volunteers": "No", "id": "NCT00010387.xml"}